CXCL8 and ovarian carcinoma: Both anti-CTAG1 and anti-IL-8 have been detected >18 months prior to diagnosis in women destined to develop ovarian cancer, exhibiting sensitivities of 23% and 15% respectively at 98% specificity (Anna Lokshin, personal communication).